Date: 2017-05-31
Type of information: Research agreement
Compound: novel Chimeric Antigen Receptor (CAR) T-cell therapeutics using antibody targeting sequences derived from MabVax's fully-human antibodies (HuMab-5B1)
Company: MabVax Therapeutics (USA - CA) Memorial Sloan Kettering Cancer (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: research - R&D
Action mechanism:
- cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy.
Disease: pancreatic cancer, small cell lung cancer, and other solid tumor cancers
Details:
- • On May 31, 2017, MabVax Therapeutics announced it entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center for the development of novel Chimeric Antigen Receptor (CAR) T-cell therapeutics using antibody targeting sequences derived from MabVax's fully-human antibodies for pancreatic, small cell lung, and other solid tumor cancers.
The research program will evaluate in xenograft models of pancreatic and small cell lung cancer targeting sequences from MabVax's leading monoclonal antibody clinical development candidate HuMab-5B1. Multiple CAR T-cell constructs have been created and tested in cell based assays demonstrating utility and warranting continued testing in animal models of pancreatic cancer and other CA19-9 expressing tumors.
MabVax has provided a second set of novel antibody targeting sequences from its clinical and research programs to MSK for development into new CAR T-cell constructs for the treatment of solid tumors. MSK will evaluate the new CAR T-cell constructs and test in both in vitro and in animal models of solid tumors with a goal of completing investigational new drug (IND) enabling pre-clinical studies. The work will be conducted in the laboratory of Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering and Gene Transfer and Gene Expression at MSK.
MabVax has certain rights to the new CAR T-cell inventions developed during the collaboration, including an exclusive time-limited option to license MSK's rights in such inventions.
Financial terms: Under the new agreement, MabVax will provide funding to evaluate the efficacy of multiple CAR T-cell products incorporating several different antibody targeting sequences.
Latest news:
Is general: Yes
